3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Lymphoma
3
Leukemia, Myeloid, Acute
3
Lymphoma, B-Cell
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Neuroblastoma
1
Myelodysplastic Syndromes
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Immunoblastic Lymphadenopathy
1
Enteropathy-Associated T-Cell Lymphoma
1
Interventions
Nivolumab
39
pembrolizumab
30
cabozantinib
29
Specimen Handling
25
Magnetic Resonance Spectroscopy
22
Ipilimumab
20
lenvatinib
16
Axitinib
15
belzutifan
13
CTLA-4 Antigen
10
Sunitinib
9
Biopsy
9
Radiosurgery
8
atezolizumab
7
Immunoglobulin G
5
toripalimab
4
fludarabine
4
avelumab
4
aldesleukin
4
Everolimus
4
Disulfides
4
Cyclophosphamide
4
zimberelimab
3
tivozanib
3
spartalizumab
3
pazopanib
3
palbociclib
3
durvalumab
3
cemiplimab
3
X-Rays
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
etoposide phosphate
×
90 days
×
Clear all
No trials found.